Liposomal amphotericin B for the treatment of visceral leishmaniasis - PubMed (original) (raw)

. 2006 Oct 1;43(7):917-24.

doi: 10.1086/507530. Epub 2006 Aug 28.

Jill Adler-Moore, Juan Berenguer, Marleen Boelaert, Margriet den Boer, Robert N Davidson, Concepcion Figueras, Luigi Gradoni, Dimitris A Kafetzis, Koert Ritmeijer, Eric Rosenthal, Catherine Royce, Rosario Russo, Shyam Sundar, Jorge Alvar

Affiliations

Liposomal amphotericin B for the treatment of visceral leishmaniasis

Caryn Bern et al. Clin Infect Dis. 2006.

Abstract

During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources